Crystal structures of two potent nonamidine inhibitors bound to factor Xa

被引:87
作者
Adler, M [1 ]
Kochanny, MJ [1 ]
Ye, B [1 ]
Rumennik, G [1 ]
Light, DR [1 ]
Biancalana, S [1 ]
Whitlow, M [1 ]
机构
[1] Berlex Biosci, Richmond, CA 94804 USA
关键词
D O I
10.1021/bi0264061
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There has been intense interest in the development of factor Xa inhibitors for the treatment of thrombotic diseases. Our laboratory has developed a series of novel non-amidine inhibitors of factor Xa. This paper presents two crystal structures of compounds from this series bound to factor Xa. The first structure is derived from the complex formed between factor Xa and compound 1. Compound 1 was the first non-amidine factor Xa inhibitor from our lab that had measurable potency in an in vitro assay of anticoagulant activity. The second compound, 2, has a molar affinity for factor Xa (K-iapp) of 7 pM and good bioavilability. The two inhibitors bind in an L-shaped conformation with a chloroaromatic ring buried deeply in the S1 pocket. The opposite end of these compounds contains a basic substituent that extends into the S4 binding site. A chlorinated phenyl ring bridges the substituents in the S1 and S4 pockets via amide linkers. The overall conformation is similar to the previously published structures for amidine-based inhibitors complexed with factor Xa. However, there are significant differences in the interactions between the inhibitor and the protein at the atomic level. Most notably, there is no group that forms a salt bridge with the carboxylic acid at the base of the S1 pocket (Asp 189). Each inhibitor forms only one well-defined hydrogen bond to the protein. There are no direct charge-charge interactions. The results indicate that electrostatic interactions play a secondary role in the binding of these potent inhibitors.
引用
收藏
页码:15514 / 15523
页数:10
相关论文
共 31 条
[21]   AMORE - AN AUTOMATED PACKAGE FOR MOLECULAR REPLACEMENT [J].
NAVAZA, J .
ACTA CRYSTALLOGRAPHICA SECTION A, 1994, 50 :157-163
[22]   Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis [J].
Nicolini, FA ;
Lee, P ;
Malycky, JL ;
Lefkovits, J ;
KottkeMarchant, K ;
Plow, EF ;
Topol, EJ .
BLOOD COAGULATION & FIBRINOLYSIS, 1996, 7 (01) :39-48
[23]   Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite [J].
Nienaber, VL ;
Davidson, D ;
Edalji, R ;
Giranda, VL ;
Klinghofer, V ;
Henkin, J ;
Magdalinos, P ;
Mantei, R ;
Merrick, S ;
Severin, JM ;
Smith, RA ;
Stewart, K ;
Walter, K ;
Wang, JY ;
Wendt, M ;
Weitzberg, M ;
Zhao, XM ;
Rockway, T .
STRUCTURE, 2000, 8 (05) :553-563
[24]   STRUCTURE OF HUMAN DES(1-45) FACTOR-XA AT 2.2-ANGSTROM RESOLUTION [J].
PADMANABHAN, K ;
PADMANABHAN, KP ;
TULINSKY, A ;
PARK, CH ;
BODE, W ;
HUBER, R ;
BLANKENSHIP, DT ;
CARDIN, AD ;
KISIEL, W .
JOURNAL OF MOLECULAR BIOLOGY, 1993, 232 (03) :947-966
[25]   Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors [J].
Phillips, G ;
Davey, DD ;
Eagen, KA ;
Koovakkat, SE ;
Liang, A ;
Ng, HP ;
Pinkerton, M ;
Trinh, L ;
Whitlow, M ;
Beatty, AM ;
Morrissey, MM .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (10) :1749-1756
[26]   Discovery of N-[2-[5-[amino(imino)methyl]-2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylglycine (ZK-807834):: A potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa [J].
Phillips, GB ;
Buckman, BO ;
Davey, DD ;
Eagen, KA ;
Guilford, WJ ;
Hinchman, J ;
Ho, E ;
Koovakkat, S ;
Liang, A ;
Light, DR ;
Mohan, R ;
Ng, HP ;
Post, JM ;
Shaw, KJ ;
Smith, D ;
Subramanyam, B ;
Sullivan, ME ;
Trinh, L ;
Vergona, R ;
Walters, J ;
White, K ;
Whitlow, M ;
Wu, S ;
Xu, W ;
Morrissey, MM .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (19) :3557-3562
[27]   CRYSTAL-STRUCTURES OF FACTOR XA SPECIFIC INHIBITORS IN COMPLEX WITH TRYPSIN - STRUCTURAL GROUNDS FOR INHIBITION OF FACTOR XA AND SELECTIVITY AGAINST THROMBIN [J].
STUBBS, MT ;
HUBER, R ;
BODE, W .
FEBS LETTERS, 1995, 375 (1-2) :103-107
[28]  
Stubbs MT, 2002, CHEMBIOCHEM, V3, P246, DOI 10.1002/1439-7633(20020301)3:2/3<246::AID-CBIC246>3.0.CO
[29]  
2-#
[30]   Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position [J].
Tucker, TJ ;
Brady, SF ;
Lumma, WC ;
Lewis, SD ;
Gardell, SJ ;
Naylor-Olsen, AM ;
Yan, YW ;
Sisko, JT ;
Stauffer, KJ ;
Lucas, BJ ;
Lynch, JJ ;
Cook, JJ ;
Stranieri, MT ;
Holahan, MA ;
Lyle, EA ;
Baskin, EP ;
Chen, IW ;
Dancheck, KB ;
Krueger, JA ;
Cooper, CM ;
Vacca, JP .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (17) :3210-3219